Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 30, 2023 05:59 ET | Source: Emergent BioSolutions

Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

Emergent has officially shipped its over the counter, original prescription strength NARCAN® Naloxone HCl Nasal Spray 4 mg to leading mass, drug/pharmacy and grocery stores, as well as online...
August 08, 2023 16:31 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results for Second Quarter 2023

Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56MUpdates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues ...
August 08, 2023 07:15 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position

Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost savings over $100 million annually GAITHERSBURG, Md.,...
July 31, 2023 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

GAITHERSBURG, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development...
July 25, 2023 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023

GAITHERSBURG, Md., July 25, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial...
July 20, 2023 18:03 ET | Source: Emergent BioSolutions

Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use

Emergent has been delivering CYFENDUS™ vaccine to the U.S. Department of Health and Human Services since 2019, under pre-Emergency Use Authorization status, and will continue to work with the U.S....
June 27, 2023 07:55 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces CEO Transition

Robert G. Kramer Sr. to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today...
May 15, 2023 07:58 ET | Source: Emergent BioSolutions

Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic

GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At...
May 11, 2023 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT

GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live...
May 09, 2023 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Financial Results For First Quarter 2023

Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101MUpdates FY 2023 guidance and provides initial Q2 2023 guidance ...